UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers

Biological psychiatry (1969), 2010-04, Vol.67 (8), p.715-721

2010

Volltextzugriff (PDF)

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

NPJ primary care respiratory medicine, 2021-12, Vol.31 (1), p.49-49, Article 49

2021

Volltextzugriff (PDF)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Human vaccines & immunotherapeutics, 2017-07, Vol.13 (7), p.1640-1652

2017

Volltextzugriff (PDF)

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

NPJ primary care respiratory medicine, 2018-08, Vol.28 (1), p.32-9, Article 32

2018

Volltextzugriff (PDF)

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Pulmonary therapy, 2019-12, Vol.5 (2), p.191-200

2019

Volltextzugriff (PDF)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

Pulmonary therapy, 2019-06, Vol.5 (1), p.69-80

2019

Volltextzugriff (PDF)

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Multidisciplinary respiratory medicine, 2018-10, Vol.13 (1), p.38-38, Article 38

2018

Volltextzugriff (PDF)

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

Pulmonary therapy, 2019-12, Vol.5 (2), p.179-190

2019

Volltextzugriff (PDF)

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

The pharmacogenomics journal, 2008-12, Vol.8 (6), p.391-399

2008

Volltextzugriff (PDF)

DESCRIPTION OF EXACERBATION HISTORY PRIOR TO INITIAL MAINTENANCE THERAPY AMONG PATIENTS WITH COPD IN THE UNITED STATES

Chest, 2019-10, Vol.156 (4), p.A452-A453

2019

Volltextzugriff (PDF)

UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION

Chest, 2020-10, Vol.158 (4), p.A1716-A1717

2020

Volltextzugriff (PDF)

MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO)

Chest, 2020-10, Vol.158 (4), p.A1720-A1721

2020

Volltextzugriff (PDF)

IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS

Chest, 2020-10, Vol.158 (4), p.A1718-A1719

2020

Volltextzugriff (PDF)

ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD

Chest, 2018-10, Vol.154 (4), p.767A-768A

2018

Volltextzugriff (PDF)

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

Journal of neurogenetics, 2009, Vol.23 (3), p.252-261

2009

Volltextzugriff (PDF)

COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL

Chest, 2019-10, Vol.156 (4), p.A470-A473

2019

Volltextzugriff (PDF)

COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL

Chest, 2019-10, Vol.156 (4), p.A475-A478

2019

Volltextzugriff (PDF)

Nicotine dependence: biology, behavior, and treatment

Annual review of medicine, 2009-01, Vol.60 (1), p.247-260

2009

Volltextzugriff (PDF)

Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators

Postgraduate medicine, 2020-02, Vol.132 (2), p.198-205

2020

Volltextzugriff (PDF)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease, 2019-08, p.1721

2019

Volltextzugriff (PDF)

Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines

Expert review of vaccines, 2016-02, Vol.15 (2), p.201-214

2016

Volltextzugriff (PDF)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.1149-1161

2021

Volltextzugriff (PDF)

Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting

Journal of the American Pharmacists Association, 2019-07, Vol.59 (4), p.479-488.e1

2019

Volltextzugriff (PDF)

Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β 2 -agonist bronchodilators

Postgraduate medicine, 2020-03, Vol.132 (2), p.198-205

2020

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(50)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(23)
Humans
(18)
Chronic Obstructive Pulmonary Disease
(8)
Copd
(8)
Patients
(8)
Respiratory System
(8)
Biological And Medical Sciences
(7)
Medicine & Public Health
(7)
Nicotine
(7)
Genetics & Heredity
(6)
Internal Medicine
(6)
Medical Research
(6)
Medical Sciences
(6)
Medicine
(6)
Original Research
(6)
Pharmacogenetics
(6)
Pneumology/respiratory System
(6)
Pharmacotherapy
(5)
Quality Of Life Research
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers

Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

DESCRIPTION OF EXACERBATION HISTORY PRIOR TO INITIAL MAINTENANCE THERAPY AMONG PATIENTS WITH COPD IN THE UNITED STATES

UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION

MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO)

IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS

Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study

ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL

COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL

Nicotine dependence: biology, behavior, and treatment

Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease

Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities

Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting

Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β 2 -agonist bronchodilators

Aktive Filter

Suchergebnisse filtern